Stay updated with breaking news from Liminal Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras Analysis of PK data from Phase 1 Multi-Ascending Dose clinical trial completed ... | March 14, 2022
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written...
LAVAL, QC, and CAMBRIDGE, ENGLAND, March 7, 2022 /PRNewswire/ -- Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written...
Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1MImmediate termination of Loan Agreement and release of security interests over all